Details

Autor(en) / Beteiligte

• Zhu, Sha
• Bao, Yige
• Zheng, Linmao
• Zhao, Jinge
• Chen, Yuntian
• Huang, Rui
• Sun, Guangxi
• Zhao, Fengnian
• Zhang, Xingming
• Liang, Jiayu
• Chen, Junru
• Wang, Zhipeng
• Ni, Yuchao
• Chen, Ni
• Shen, Pengfei
• Zeng, Hao

Titel

Chronological Liquid Biopsy Reveals the Impact of Platinum-Based Chemotherapy on a Prostate Cancer Patient’s CDK12 Mutation: A Case Report

Ist Teil von

• OncoTargets and therapy, 2022-09, Vol.15, p.947-952

Ort / Verlag

Macclesfield: Dove Medical Press Limited

Erscheinungsjahr

2022

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• CDK12 (Cyclin-Dependent Kinase 12)-mutated prostate cancer patients often respond badly to current therapies. Immunotherapy and platinum-based chemotherapy are recommended based on the molecular features of CDK12-mutated tumors, but the reported patient outcomes are still unsatisfying. Here we report a prostate cancer patient with CDK12 somatic mutation who received multiple therapy options, including platinum-based chemotherapy and immunotherapy. His sequential circulating tumor DNA (ctDNA) -based liquid biopsy tests showed that his original CDK12 mutation fell undetectable twice. This phenomenon was observed only when he was responding well to platinum-based chemotherapy. His responses to immunotherapy were not satisfying. This case indicates that platinum-based chemotherapy can be a good option for treating patients with CDK12 mutation. More importantly, dynamic ctDNA-based liquid biopsies to monitor patients' CDK12 mutation status are critical in evaluating patients' response and tolerance during platinum-based chemotherapy, therefore may lead to a better overall prognosis. In conclusion, CDK12-mutated prostate cancer patients are likely to benefit from platinum-based chemotherapy, especially with the help of dynamic ctDNA-based liquid biopsies to monitor their CDK12 mutation status. Keywords: CDK12, liquid biopsy, platinum, prostate cancer, case report